Finepoint Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Finepoint Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-728,602	Closed	-$32.2M	–	23
2025 Q1	$32.2M	Sell	728,602 -20,150	-3%	-$928K	2.45%	5
2024 Q4	$27.1M	Buy	748,752 +97,900	+15%	+$3.42M	1.65%	8
2024 Q3	$20.9M	Buy	650,852 +12,500	+2%	+$467K	1.52%	9
2024 Q2	$24M	Buy	638,352 +45,824	+8%	+$1.93M	6.83%	4
2024 Q1	$29.2M	Buy	592,528 +35,600	+6%	+$1.65M	7.48%	2
2023 Q4	$20.3M	Hold	556,928	–	–	6.41%	7
2023 Q3	$12.9M	Sell	556,928 -51,700	-8%	-$1.41M	6.41%	7
2023 Q2	$16M	Sell	608,628 -5,603	-0.9%	-$147K	5.52%	8
2023 Q1	$15.8M	Sell	614,231 -28,769	-4%	-$841K	6.04%	11
2022 Q4	$16.7M	Buy	643,000 +334,908	+109%	+$8.25M	5.41%	10
2022 Q3	$8.79M	Buy	+308,092	New	+$8.83M	2.89%	18

Other funds holding SWTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Finepoint Capital's SWTX Position: Q2 2025 in Review

Finepoint Capital sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 728,602 shares — an estimated $32.2M sold.

Finepoint Capital first reported a position in SWTX in Q3 2022 and held it in 11 quarters. The position peaked at $32.2M in Q1 2025. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

Finepoint Capital reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
Finepoint Capital sold 728,602 SpringWorks Therapeutics shares in Q2 2025, an estimated $32.2M.
Finepoint Capital first reported a position in SpringWorks Therapeutics in Q3 2022 and held it in 11 quarters.
Finepoint Capital's SpringWorks Therapeutics position peaked at $32.2M in Q1 2025.
222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Finepoint Capital's 13F filing for Q2 2025, filed 13 Aug 2025.